Clinical Randomisation of an Antifibrinolytic in Significant Head Injury
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
The CRASH-3 trial will provide reliable evidence about the effect of tranexamic acid on
mortality and disability in patients with traumatic brain injury. The effect of tranexamic
acid on the risk of vascular occlusive events and seizures will also be assessed.
Additionally, a nested study will be conducted in a subset of CRASH-3 trial participants.
This nested study (CRASH-3 Intracranial Bleeding Sub-Study [CRASH-3 IBS]) will examine the
effect of tranexamic acid on intracranial haemorrhage and cerebral ischaemia using CT Scans
in approximately 1,000 patients randomised into the CRASH-3 trial.